These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 33733956)

  • 1. Fab-Nanolipoprotein Conjugate Causes Vitreous Opacity and Cataracts Following a Single Intravitreal Administration in New Zealand White Rabbits.
    Tassew NG; Laing ST; Shatz W; Crowell SR; Loyet KM; Schuetz C; Blanchette C
    Toxicol Pathol; 2021 Apr; 49(3):647-655. PubMed ID: 33733956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retinal and Lens Degeneration in New Zealand White Rabbits Administered Intravitreal TSG-6 Link Domain-Rabbit FAb Fusion Proteins.
    Laing ST; Tassew N; Tesar D; Wang Y; Crowell SR; Gray J; Kwong M; Loyet KM; Andaya R; Kusi A; Kelley RF
    Toxicol Pathol; 2021 Apr; 49(3):634-646. PubMed ID: 33349160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ocular toxicity of intravitreal clarithromycin.
    Unal M; Peyman GA; Liang C; Hegazy H; Molinari LC; Chen J; Brun S; Tarcha PJ
    Retina; 1999; 19(5):442-6. PubMed ID: 10546942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ocular and systemic toxicity of intravitreal topotecan in rabbits for potential treatment of retinoblastoma.
    Buitrago E; Del Sole MJ; Torbidoni A; Fandino A; Asprea M; Croxatto JO; Chantada GL; Bramuglia GF; Schaiquevich P
    Exp Eye Res; 2013 Mar; 108():103-9. PubMed ID: 23333535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ocular toxicity study of trypan blue injected into the vitreous cavity of rabbit eyes.
    Veckeneer M; van Overdam K; Monzer J; Kobuch K; van Marle W; Spekreijse H; van Meurs J
    Graefes Arch Clin Exp Ophthalmol; 2001 Sep; 239(9):698-704. PubMed ID: 11688671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of vitreous clearance and potential retinal toxicity of intravitreal lornoxicam (xefo).
    Diakonis VF; Tsourdou A; Tzatzarakis MN; Tsika C; Charisis S; Naoumidi I; Plainis S; Tsilimbaris MK
    J Ocul Pharmacol Ther; 2013 Sep; 29(7):627-32. PubMed ID: 23556534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody Format and Serum Disposition Govern Ocular Pharmacokinetics of Intravenously Administered Protein Therapeutics.
    Shivva V; Boswell CA; Rafidi H; Kelley RF; Kamath AV; Crowell SR
    Front Pharmacol; 2021; 12():601569. PubMed ID: 34025395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ocular tissue distribution and pharmacokinetic study of a small 13kDa domain antibody after intravitreal, subconjuctival and eye drop administration in rabbits.
    Gough G; Szapacs M; Shah T; Clements P; Struble C; Wilson R
    Exp Eye Res; 2018 Feb; 167():14-17. PubMed ID: 29074387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravitreal sustained-release cyclosporine in the treatment of experimental uveitis.
    Jaffe GJ; Yang CS; Wang XC; Cousins SW; Gallemore RP; Ashton P
    Ophthalmology; 1998 Jan; 105(1):46-56. PubMed ID: 9442778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Binding to Ocular Albumin as a Half-Life Extension Principle for Intravitreally Injected Drugs: Evidence from Mechanistic Rat and Rabbit Studies.
    Fuchs H; Igney F
    J Ocul Pharmacol Ther; 2017 Mar; 33(2):115-122. PubMed ID: 28055308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distribution and metabolism of intravitreal cidofovir and cyclic HPMPC in rabbits.
    Cundy KC; Lynch G; Shaw JP; Hitchcock MJ; Lee WA
    Curr Eye Res; 1996 May; 15(5):569-76. PubMed ID: 8670758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravitreal sustained-release dexamethasone device in the treatment of experimental uveitis.
    Cheng CK; Berger AS; Pearson PA; Ashton P; Jaffe GJ
    Invest Ophthalmol Vis Sci; 1995 Feb; 36(2):442-53. PubMed ID: 7843913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and toxicity of intravitreal chemotherapy for primary intraocular lymphoma.
    Velez G; Yuan P; Sung C; Tansey G; Reed GF; Chan CC; Nussenblatt RB; Robinson MR
    Arch Ophthalmol; 2001 Oct; 119(10):1518-24. PubMed ID: 11594954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of intravitreal triamcinolone acetonide on susceptibility to experimental bacterial endophthalmitis and subsequent response to treatment.
    Bucher RS; Hall E; Reed DM; Richards JE; Johnson MW; Zacks DN
    Arch Ophthalmol; 2005 May; 123(5):649-53. PubMed ID: 15883284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Intraocular implantation of cyclosporine A drug delivery system in the treatment of experimental uveitis].
    Dong XG; Xu YM; Yuan GQ; Shi WY; Xie LX; Wang SG
    Zhonghua Yan Ke Za Zhi; 2005 Jul; 41(7):636-41. PubMed ID: 16080900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tolerability and pharmacokinetics of intravitreal sirolimus.
    Mudumba S; Bezwada P; Takanaga H; Hosoi K; Tsuboi T; Ueda K; Kawazu K; Ali Y; Naor J
    J Ocul Pharmacol Ther; 2012 Oct; 28(5):507-14. PubMed ID: 22662868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and Bioavailability of Complete and Half-Dose Intravitreal Ziv-Aflibercept in an Experimental Model: Contralateral Eye Study.
    Lashay A; Delrish E; Ashrafi E; Movassat M; Asadi-Amoli F; Dinarvand R; Abrishami M
    Ophthalmic Surg Lasers Imaging Retina; 2019 Dec; 50(12):785-790. PubMed ID: 31877224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravitreal Pharmacokinetic Study of the Antiangiogenic Glycoprotein Opticin.
    Del Amo EM; Griffiths JR; Klaska IP; Hoke J; White A; Aarons L; Cooper GJS; Bainbridge JWB; Bishop PN; Unwin RD
    Mol Pharm; 2020 Jul; 17(7):2390-2397. PubMed ID: 32437164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of Melphalan After Intravitreal Injection in a Rabbit Model.
    Buitrago E; Winter U; Williams G; Asprea M; Chantada G; Schaiquevich P
    J Ocul Pharmacol Ther; 2016 May; 32(4):230-5. PubMed ID: 26785130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of intravitreal bevacizumab in experimental posterior penetrating eye injury.
    Mehdizadeh M; Fattahi F; Eghtedari M; Nowroozzadeh MH; Toosi F
    Retina; 2011 Jan; 31(1):154-60. PubMed ID: 20838359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.